Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Rebecca Chambers, Ross Fitzgerald

Premium

Illumina has appointed Rebecca Chambers to senior director of investor relations. She joins the company from Myriad Genetics, where she was director of relations and corporate communications. Previously, she was senior manager of investor relations at Life Technologies. She holds an MBA from Cornell University and a BS in biology from John Carroll University.


Ross Fitzgerald, who is a group leader at the Roslin Institute in the UK, has been named chair in molecular biology at the University of Edinburgh. Fitzgerald's research focuses on using genomic and molecular tools to understand staphylococcal diseases, with the goal of identifying new therapeutic and diagnostic approaches.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.